News Boehringer drug scores in another pulmonary fibrosis trial Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings.
News Boehringer drug for brain fog in schizophrenia fails trial Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.
Sales & Marketing A next-generation mindset: Veeva Commercial Summit 2024 Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.
Patients Keeping stigma out of it: Personalising the mental health co... Thursday 10th October was World Mental Health Day, focused this year on ‘mental health at work’.
News Ono, Boehringer add to cancer pipelines with licensing deals Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.
R&D Boehringer Ingelheim and Veeva: A data partnership for One M... Boehringer’s Medicine Excellence initiative harnesses technology with the aim to build a ‘One Medicine Platform’, unifying development processes and data in a centralised platform.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.